Comparative Pharmacology
Head-to-head clinical analysis: ENSKYCE versus MARLISSA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ENSKYCE versus MARLISSA.
ENSKYCE vs MARLISSA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ENSKYCE (fospropofol disodium) is a prodrug of propofol. It is hydrolyzed by alkaline phosphatases to release propofol, which acts as a positive allosteric modulator of GABA-A receptors, enhancing chloride conductance and producing sedation and anesthesia.
MARLISSA is a combination of ethinyl estradiol, a synthetic estrogen, and drospirenone, a progestin with antimineralocorticoid and antiandrogenic activity. It suppresses gonadotropins, inhibiting ovulation, and alters cervical mucus and endometrial lining.
2 g IV every 8 hours over 5 hours on days 1-3 of each 21-day cycle
MARLISSA 20 mg orally once daily with or without food.
None Documented
None Documented
12 hours (terminal); allows once-daily dosing in most patients
Terminal elimination half-life is 12-18 hours (mean 15 hours) in healthy adults. In moderate-to-severe hepatic impairment, half-life may be prolonged to 30-40 hours; no significant change in renal impairment.
Renal: ~70% unchanged; Biliary/Fecal: ~20% as metabolites
Primarily renal (75-80% as unchanged drug) via glomerular filtration and tubular secretion; 10-15% fecal via biliary excretion; 5-10% metabolized with metabolites also renally eliminated.
Category C
Category C
Oral Contraceptive
Oral Contraceptive